Kornimate/medical-research-clean huggingface dataset:
trough bronchoprotection conferred by levosalbutamol and racemic salbutamol

Conditions: Asthma

Summary: the objective of this study is to compare the relative bronchoprotection (at trough) conferred by 2-week chronic dosing with levosalbutamol and racemic salbutamol in mild to moderate asthmatics. patients will be preselected into two groups on the basis of their beta-2 adrenoreceptor polymorphisms. the investigators will evaluate if this has a differential effect on the bronchoprotection conferred by both formulations of salbutamol, as evidenced by a rebound in airway hyper-responsiveness, in order to determine whether any effect can be explained by the s enantiomer in the racemic formulation.


Eligibility criteria:
inclusion criteria: 1. mild to moderate stable asthmatics on ≤ 2000μg bdp or equivalent, who are methacholine responsive pc20\< 4 mg/ml 2. \>1dd change in methacholine pc20 after the administration of racemic salbutamol. 3. male or female 18-65 4. informed consent 5. ability to comply with the requirements of the protocol exclusion criteria: 1. severe asthmatics as defined by an fev1≤ 60% or pef variability \> 30% or with continual daytime or nocturnal symptoms. 2. the use of oral corticosteroids within the last 3 months. 3. recent respiratory tract infection (2 months). 4. significant concomitant respiratory disease such as copd, cf, abpa, bronchiectasis and active pulmonary tuberculosis. 5. any other clinically significant medical condition such as unstable angina, acute myocardial infarction in the preceding 3 months, recent tia/ cva, that may endanger the health or safety of the participant, or jeopardise the protocol. 6. any significant abnormal laboratory result as deemed by the investigators 7. pregnancy, planned pregnancy or lactation 8. known or suspected contra-indication to any of the imp's 9. concomitant use of medicines (prescribed, over the counter or herbal) that may interfere with the trial.

Keywords: asthma genotype beta2adrenoreceptor levosalbutamol
immune reconstitution in tuberculosis disease

Conditions: Pulmonary Tuberculosis (TB)

Summary: the aim with study is to provide adjunctive therapy with vitamin d and phenylbutyrate together with standard anti-tuberculosis treatment to significantly improve clinical recovery among patients with untreated, active pulmonary tuberculosis.


Eligibility criteria:
inclusion criteria: hiv negative patients, adult patients \>18 years who has not started anti-tb therapy. newly diagnosed pulmonary tb confirmed by microscopy or culture but also sputum-negative clinical tb cases (defined according to the who 2006 criteria for sputum smear-negative tb ie. clinical symptoms of tb, chest x-ray findings and response to standard treatment). exclusion criteria: patients who have already started treatment with anti-tb drugs for more that 5 days. hiv-positive patients. history of anti-tb treatment in the past 2 years. local extra-pulmonary tb in the absence of lung manifestations. hypercalcaemia (serum calcium \> 3 mmol/l) identified at baseline. pregnant and breast feeding women. any known liver or kidney function abnormality, malignancy or patients treated with cardiac glycosides.

Keywords: pulmonary tb cholecalciferol sodium phenylbutyrate antimicrobial peptides immune response
photoacoustic imaging (pai) of the prostate: a clinical feasibility study

Conditions: Prostate Cancer

Summary: the purpose of our study is to image human prostate tissue using a transrectal photoacoustic imaging probe.

primary objective(s): the primary objective of this pilot study is to assess pai-performance in a clinical setting to understand limitations of our current pai instrumentation and to help improve the next-generation design. secondary objective(s): to do preliminary evaluations of oxygen saturation in lesions based on pai-measurements in order to distinguish malignant from benign prostatic tissue as a basis for future studies.

Eligibility criteria:
inclusion criteria: * consent signed * male \>= 18 and \<= 80 years of age * patients must have an elevated psa and/ or abnormal digital rectal exam or other indication for prostate biopsy or patients with biopsy proven prostate cancer who are scheduled for prostatectomy. exclusion criteria: * history of prostatectomy or other surgical history that would preclude transrectal imaging (i.e. abdominal perineal resection), anal stenosis/stricture disease * men with anatomic abnormalities or previous surgical history that make transrectal imaging impossible (for example, men with previous abdominal-perineal bowel resections or anal atresia/stenosis)
a research study on how nnc0487-0111, a new medicine, works in chinese participants after 10 days of oral dosing

Conditions: Overweight; Obesity

Summary: the study is testing a new study medicine called nnc0487-0111 for weight control in chinese people with body mass index (bmi) greater than or equal to (\>=) 24 kilogram per square meter (kg/m\^2). the aim of this study is to find out how safe the study medicine is and how it behaves in your body. participants will either get nnc0487-0111 or placebo. which treatment participants will get is decided by chance. oral nnc0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. the study will last for about 60 days.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * male chinese participants, age 18-55 years (both inclusive) at the time of signing the informed consent. * body mass index (bmi) between 24.0 and 34.9 kilogram per square meter (kg/m\^2)(both inclusive), with a body weight greater than or equal to (\>=) 65.0 kilogram (kg), at screening. * considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: * any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol * glycated haemoglobin (hba1c) greater than or equal to (\>=) 6.5 percent (%) (48 millimoles per mole \[mmol/mol\]) at screening * any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values: * vitamin d (25-hydroxycholecalciferol) less than (\<) 12 nanograms per millilitre (ng/ml) (30 nanometer\[nm\]) at screening * parathyroid hormone (pth) outside normal range at screening * total calcium outside normal range at screening * amylase greater than or equal to (\>=) 2 times upper limit of normal at screening * lipase greater than or equal to (\>=) 2 times upper limit of normal at screening * calcitonin greater than or equal to (\>=) 50 picograms per milliliter (pg/ml) at screening
autologous mesenchymal stem cells for the treatment of neuromyelitis optica spectrum disorders

Conditions: Devic's Syndrome; Devic's Neuromyelitis Optica; Devic Syndrome; Devic's Disease; Devic Disease

Summary: neuromyelitis optica (nmo) is a demyelinating and degenerative disorder of the central nervous system affecting vision and brain and spinal cord function which leads to accumulating disability with a 5 year-mortality of approximately 30%. survivors are typically left with severe morbidity secondary to blindness, quadriparesis and respiratory failure. no agent has been found to be highly effective in halting disease activity.based on recent outcomes of multipotent mesenchymal stromal cells in autoimmune diseases including multiple sclerosis, and based on the mechanisms of neuromyelitis optica, the investigators anticipate that mesenchymal stem cells transplantation may provide lasting disease stability for neuromyelitis optica patients.

primary objective was to assess feasibility and safety; the investigators compared adverse events from up to 3months before treatment until up to 12 months after the infusion. as a secondary objective, the investigators chose efficacy outcomes to assess the expanded disability status (edss)、annual relapse rate (arr) and time to next relapse after transplant. third objective anterior visual pathway and pyramidal tract as a model of wider disease. masked endpoint analyses was used for electrophysiological and selected imaging outcomes.

Eligibility criteria:
inclusion criteria: * clinically definite neuromyelitis optica or neuromyelitis optica spectrum disorder * age \> 18 year * edss \> 3 * progression continued relapses or worsening mri after at least a year of attempted therapy as evidenced by one or more of the following: * increase of 1 edss point (if baseline edss\ 5.5) * moderate-severe relapses in past 18 months * gadolinium enhancing lesions (double or triple dose gd) * 1 new t2 lesion * evidence of recent inflammatory disease, as evidenced by any one of the following: * 1 moderate-severe relapses in past 18 months * 1 gd-enhancing lesions (single, double or triple dose gd) * 1 new t2 lesion exclusion criteria: * received immune inhibitors immunomodulator during the three months before the trial * significant cardiac, renal, or hepatic failure or any other disease that may affect the results of the study * allergies * pregnant or possibly pregnant * cognitive decline to understand or sign the informed consent * brain tumor, hiv (+) tumor marker (+), blood pressure (bp): 200 /110 mmhg * judged not suitable by doctors

Keywords: autologous mesenchymal stem cells neuromyelitis optica treatment
are there differences in postoperative pain between bupivacaine and lidocaine for carpal tunnel release?

Conditions: Carpal Tunnel Syndrome; Carpal Tunnel

Summary: the goal of this clinical trial is to compare the use of bupivacaine and lidocaine as local anesthetics in carpal tunnel release surgery. the main questions it aims to answer are: * are there any differences in pain after surgery? * are there any differences in postoperative analgesic consumption?

the wide-awake local anesthesia no tourniquet (walant) technique has become popular for hand surgery in the past decade. it consists of injecting a local anesthetic and epinephrine into the surgical site. lidocaine, a short-acting local anesthetic, is used in the classic description. adding a long-acting local anesthetic, such as bupivacaine, has been suggested for long surgeries. however, the use of bupivacaine in shorter-duration procedures could combine the advantages of ambulatory surgery without a tourniquet with long-acting analgesia, improving postoperative pain and reducing the consumption of analgesics. patients undergoing first-time open carpal tunnel release surgery will be randomized to receive bupivacaine or lidocaine. randomization will be generated by computer using random block sizes of 2 or 4 with an allocation ratio of 1:1. postoperatively, patients will receive standard medical care. it consists of 50 mg of diclofenac to take when they feel pain (with a minimum interval of 8 hours). patients will be instructed to complete a medication log for pain and analgesic consumption. a blinded investigator will contact them by phone at 24 hours and 48hs. at two weeks, they will be controlled by research staff for complications. eighty-two patients will be recruited, 41 per arm, assuming a 20% loss. the sample size was calculated using a 90% power and 5% significance level. the objective was to detect a minimum difference of 2 points on a numeric scale ranging from 0 to 10 with a standard deviation of 2.5 points.

Eligibility criteria:
inclusion criteria: * patients with carpal tunnel syndrome undergoing first-time surgery exclusion criteria: * pregnant * end-stage kidney disease * end-stage liver disease * allergy to bupivacaine, lidocaine or diclofenac * carpal tunnel revision surgery * associated surgery (e.g., trigger finger release) * unable to understand informed consent or indications * patients with anxiety related to surgery who explicitly prefer to be sedated or asleep during their surgery * preoperative american society of anaesthesiology (asa) scale ≥3

Keywords: carpal tunnel syndrome postoperative pain bupivacaine walant lidocaine
puffins brain health study

Conditions: Cerebral Small Vessel Disease

Summary: small vessel disease (svd) is a major cause of stroke and contributor to dementia cases. as work continues to develop new treatments to address the impact of svd, new imaging techniques are needed to identify and track the progression of brain changes that occur with svd. magnetic resonance imaging (mri) is the gold standard to diagnose poor brain health due to small vessel disease. however, current mri systems are expensive and complex to operate, and so access is limited. low-field mri technology, operating at magnetic field strengths many times lower than conventional mri, can make brain imaging much more cost-effective and accessible. however, further work is needed to develop low-field mri towards clinically feasible assessments of brain health. the university of aberdeen hosts a unique network of researchers and imaging technologies that is now making it possible to test and develop different low-field mri approaches towards solving key healthcare challenges. the aim of this study is to evaluate the potential of two distinct approaches, field-cycling imaging (fci) and ultra-low field mri (ulf-mri), to detect brain changes linked with small vessel disease. automated methods will be developed to analyse images and extract measurements that detect and track progression of disease severity.


Eligibility criteria:
inclusion criteria: * adults ≥ 50 years old. * subjects who do not report problems with memory. * small vessel disease (fazekas score 1 to 3). * suitable body habitus. * able to understand written and spoken english. exclusion criteria: * history of major stroke (minor stroke/transient ischaemic attacks or lacunar stroke are acceptable). * individuals unable to give informed consent. * contra-indications to mri scanning such as implantable cardiac devices.

Keywords: field-cycling imaging ultra-low field mri
efficacy and safety of dwj1248 with remdesivir in severe covid-19 patients

Conditions: Severe COVID-19

Summary: efficacy and safety of dwj1248 with remdesivir in severe covid-19 patients


Eligibility criteria:
inclusion criteria: * adults over the age of 19 as of the signed date in written consent * subjects with covid-19 according to rt-pcr test(within 10 days) * subjects who need to be hospitalized and injected remdesivir exclusion criteria: * subjects who cannot orally administer the investigational products * subjects who requiring mechanical ventilation or ecmo * acute respiratory distress syndrome(ards), shock, multiple organ dysfunction syndrome * subjects who need administration of immunosuppressants * subjects who are allergic or sensitive to investigational products or its ingredients * crcl \< 30 ml/min or egfr \< 30 ml/min/1.73m\^2 * ast or alt \>= 5xuln * subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators
endtidal carbon dioxide for earlier detection of pulmonary hypertension

Conditions: Hypertension, Pulmonary; Hypertension;Pulmonary;Primary; Chronic Thromboembolic Pulmonary Hypertension; Vascular Diseases; Lung Diseases

Summary: measurement of the endtidal carbon dioxide by capnography to exclude or to ensure the diagnosis pulmonary hypertension. the aim of the study is to obtain an endtidal carbon dioxide cut-off value for the diagnostic algorithm for pulmonary hypertension as an easily measurable and cheap diagnostic tool in patients with suspicion of pulmonary hypertension.

the disease pulmonary hypertension is due to a remodeling of the lung vessels which results in a change of the exhaled air. this change is measurable with a so called capnograph. the investigators want to measure the breath from patients with and without pulmonary hypertension to detect a cut-off value for the diagnosis pulmonary hypertension. patients which have the probably diagnosis pulmonary hypertension and are older than 18 years are investigated. this patients will get an right heart catheterization and a measurement from their exhaled air.

Eligibility criteria:
inclusion criteria: age \> 18 years, suspicion of pulmonary hypertension, planned or accomplished right heart catheterization exclusion criteria: none

Keywords: pulmonary hypertension endtidal co2 endtidal carbon dioxide pulmonary arterial hypertension
effects of a cbd and natural ingredients cream on the chronic pain of triathletes, runners, cyclists, and swimmers

Conditions: Tendinopathy; Injuries; Chronic Pain; Sports; Physical Activity

Summary: there is a high prevalence of chronic pain in our society, which is detrimental at an individual and country level. cannabidiol (cbd) has been proposed as a promising treatment for chronic pain, although more high-quality studies are needed in this area. on the other hand, triathlon, running, cycling, and swimming are sports modalities that have an increasing professionalism and importance, albeit not exempt from injuries. the main goal of this study is to assess the effectiveness of a topical treatment for recurrent chronic pain caused by tendinopathies with a cream containing cbd in triathletes, runners, cyclists, and swimmers. consequently, the research question for this study is the following: can the cbd cream be effective in treating chronic pain? the investigators hypothesize that the cream will be able to affect the pain, both in the short and the long term. the study will be interventional, with a crossover, randomized, and double-blinded design. two groups of participants will be generated, as well as two treatment options (cbd cream, and a similar one without the cbd). the subjects will apply one of the treatments for one month, followed by a wash-out week without any cream application, and another month with the other treatment. during these weeks, different parameters will be controlled via online questionnaires. the analyzed variables will include the following: chronic pain, acute pain, wellness, perceived exertion, quality of life, and satisfaction with the treatment. different statistical tests will be applied to the collected data, comparing their means and correlations to infer the results.


Eligibility criteria:
inclusion criteria: * being a federated triathlete, runner, cyclist, or swimmer. * being 18-70 years old. * having chronic pain (present at least 3 months before the beginning of the study). * having a diagnosis of patellar, achilles, or iliotibial band tendinopathy for the lower extremities, and/or shoulder rotator cuff or biceps brachii tendinopathy for the upper extremities. * training any modality of triathlon, running, cycling, or swimming 4-5 days per week with a minimal training volume of 8 hours per week. * having at least 1 year of experience training in triathlon, running, cycling, or swimming. * providing at least 80% of the needed data for the study. exclusion criteria: * pregnant women. * people allergic to any of the ingredients of the creams used. * people with skin injuries in the zones in which the cream has to be applied. * using any other pain treatments. those who use them before the study can still participate if they stop their usage 1 week before the beginning of the study.

Keywords: cbd cannabidiol triathlon chronic injuries running cycling swimming
a randomized controlled phase ii trial with intradermal imo-2125 in pathological tumor stage (p) t3-4 cn0m0 melanoma

Conditions: Malignant Melanoma

Summary: currently, there is no widely used adjuvant treatment available to improve survival after surgical excision of a primary melanoma. in a previous study, loco-regional and systemic immune stimulations, as well as favourable clinical outcomes in terms of sentinel lymph node (sln) tumor status and recurrence-free survival (rfs) in patients with clinical stage i-ii melanoma who received a low dose of toll-like receptor 9 (tlr-9) cpg7909 (cpg-b odn) intradermally at the excision site of the primary tumor prior to sln biopsy (snb) were described. in this phase ii trial the investigators had investigated the clinical activity of a next-generation cpg-odn, imo-2125, and it's ability to induce loco-regional and systemic immune stimulation in pt3-4 cn0m0 melanoma patients who are scheduled to undergo a combined re-excision and snb is


Eligibility criteria:
inclusion criteria: * 18 years or older * histologically confirmed primary malignant melanoma cutis with a breslow tumor depth \>2.0 mm * scheduled to undergo a combines re-excision and sentinel node biopsy (snb) * world health organization (who) performance status ≤1 * agreement to use effective contraceptive methods from screening until at least 90 days after the imo-2125 administration * written informed consent exclusion criteria: * known hypersensitivity to any oligodeoxynucleotide * active auto-immune disease requiring disease-modifying therapy at the tumr of screening * pathologically confirmed loco-regional or distant metastasis * non-skin melanoma * patients with another primary malignancy (some exceptions) * active systemic infections requiring antibiotics * women who are pregnant or breast-feeding